Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2022

Exosomal MiRNAs as Biomarkers for Radiation Toxicity in Breast
Cancer Patients
Mina V. McGinn
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Oncology Commons
© Mina V McGinn

Downloaded from
https://scholarscompass.vcu.edu/etd/7124

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

EXOSOMAL MIRNAS AS BIOMARKERS FOR RADIATION TOXICITY IN BREAST
CANCER PATIENTS

A thesis submitted in partial fulfillment of the requirements for the degree of Biochemistry at
Virginia Commonwealth University.
by

MINA V MCGINN
Bachelor of Science in Health Preparation and Professional Sciences, Virginia Commonwealth
University, 2016

Director: VASILY A YAKOVLEV
ASSISTANT PROFESSOR, DEPARTMENT OF RADIATION ONCOLOGY
AFFILIATE ASSISTANT PROFESSOR, DEPARTMENT OF BIOCHEMISTRY AND
MOLECULAR BIOLOGY

Virginia Commonwealth University
Richmond, VA
July, 2022

i

ACKNOWLEDGEMENTS:

I would first like to thank Dr. Vasily Yakovlev for his guidance, patience, and for the
time he has spent teaching me in his lab. I would also like to thank Dr. Jennifer Koblinski and
Dr. Larisa Litovchick for their recommendations and advice regarding my research and writing,
and for taking the time to be a part of my committee. I would also like to thank Dr. Tomasz
Kordula for helping me navigate through the process of transitioning from the Premedical
Graduate Sciences Certificate Program to the Department of Biochemistry and for always being
readily available to help all of us students.
I also want to thank the following people whose friendship and support have made the
experience of graduate school and my other academic pursuits just a little bit easier: Lisa Rupe,
Sofiya Blat, Shannon Santiago, Maysoon Saeed, and Gene Chatman Clark. Thank you as well to
my parents, my grandmother, and my future in-laws for their support and generosity during my
college journey. I would especially like to acknowledge my fiancé, Alexander Larson, and my
uncle, Frank Bossong. There is no one else in the world who believes in me and wishes for me to
succeed quite like the two of you.
Thank you to all of my above mentioned friends and family for reminding me of my
capabilities and accomplishments, offering your advice and words of encouragement, and for
being available to let me unload all of my stress, doubts, and concerns. I should also mention that
I could not have gotten this far without my coffee machine and my two cats, Benji and Tuxedo;
thank you for keeping me company during all of those late night study sessions.

ii

TABLE OF CONTENTS

Page
Acknowledgements..........................................................................................................................ii
Figures and Tables..........................................................................................................................iv
Abbreviations...................................................................................................................................v
Abstract...........................................................................................................................................vi
Chapter
1

Introduction..............................................................................................................1
Materials and Methods.............................................................................................7
Results....................................................................................................................12
Discussion..............................................................................................................24
Literature Cited......................................................................................................32

iii

LIST OF FIGURES

Figure 1: Nanoparticle tracking analysis (ZetaView®) of exosome concentration and size
representation in plasma samples...................................................................................................13
Figure 2: Analysis of the extracted exosomes...............................................................................15
Figure 3: Melting curves for 24 miRNAs demonstrated a high potential in the prediction of postRT toxicity of breast cancer patients and five miRNAs as potential normalization controls........17
Figure 4: UniSp2-4-5 expression analysis.....................................................................................19

TABLES

Table 1: Potential miRNA candidates for prediction of post-RT normal tissue toxicity and
potential normalization controls....................................................................................................18

iv

LIST OF ABBREVIATIONS

BCP

breast cancer patients

ESCRT

endosomal sorting complex required for transport

EV

extracellular vesicle

Exo-miRNA

exosomal microRNA

K2EDTA

potassium ethylene diamine tetraacetic acid

miRNA

micro RNA

mRNA

messenger RNA

NP

nanoparticle

NTA

nanoparticle tracking analysis

ROX

carboxy-X-rhodamine

RT

radiotherapy

TEM

transmission electron microscopy

WB

western blot

v

ABSTRACT

EXOSOMAL MIRNAS AS BIOMARKERS FOR RADIATION TOXICITY IN BREAST
CANCER PATIENTS

A thesis submitted in partial fulfillment of the requirements for the degree of Biochemistry at
Virginia Commonwealth University.
by

MINA V MCGINN
Bachelor of Science in Health Preparation and Professional Sciences, Virginia Commonwealth
University, 2016

Director: VASILY A YAKOVLEV
ASSISTANT PROFESSOR, DEPARTMENT OF RADIATION ONCOLOGY
AFFILIATE ASSISTANT PROFESSOR, DEPARTMENT OF BIOCHEMISTRY AND
MOLECULAR BIOLOGY

Radiotherapy (RT) is a standard treatment for most breast cancer patients (BCPs), but is
often accompanied by acute and late toxic effects in normal tissue. Exosomes are nano vesicles
about 30-150nm in size that originate from the endosomal network and are found in most body
fluids. Exosomes are a fundamental driver of intercellular communication by transferring
proteins, lipids and microRNA (miRNA). Exosomal miRNA (Exo-miRNA) signatures may serve
as non-invasive prediction biomarkers of post-radiation toxicities of BCPs.
Eighty six BCPs treated in the Radiation Oncology Department were enrolled in an IRB

vi

approved study. BCPs were evaluated weekly during RT and at prescribed intervals following
completion of RT for the development of toxicity LENT-SOMA scale. Acute toxicity effects
were assessed using physician reported toxicity scale CTCAE v4. Blood samples were collected
one day before RT. The PureExo® Exosome Isolation Kit was used to isolate exosomes from the
plasma. Exo-miRNAs were isolated and cDNA was synthesized for all samples.
Exo-miRNAs were analyzed from the plasma of BCPs divided into four groups: (1) Low
toxicity (n=9), (2) Moderate toxicity (n=45), (3) High acute toxicity (n=7), and (4) High late
toxicity (n=25). For preliminary analysis, cDNA samples in each group were pooled together and
the four groups were analyzed for the expression of 179 miRNAs commonly found in human
serum/plasma. Twenty-four out of 179 tested exo-miRNAs demonstrated a high potential in the
prediction of post-RT toxicity of BCPs.
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CHAPTER 1
INTRODUCTION

Breast cancer affects 1 in 8 women worldwide and is the second leading cause of death
due to cancer for women in the United States.1,2 Breast cancer arises from dysregulated growth
of mutated cells that begins predominantly in the luminal epithelial cells of the milk-producing
lobules and ducts of the breast.1 Continued proliferation of these abnormal cells has the potential
to metastasize to secondary sites via the blood and lymphatic vessels, further invading normal
tissues and significantly worsening patient outcomes.1 Despite the overall decrease in breast
cancer mortality over the last several decades due to improvements in diagnosis and treatment
methods, breast cancer remains the most commonly diagnosed cancer in women worldwide.2
Furthermore, the current standard treatments for cancer often take a significant physical toll on
the body despite not always being effective in improving patient prognosis.3 Thus, there is a
clear need for optimizing cancer treatment based on the genetic differences that exist between
each cancer diagnosis.

Radiotherapy is the most crucial non-surgical treatment of cancer. This treatment is
administered in over half of all breast cancer cases.3 Radiotherapy induces cellular damage by
exploiting the tumor cells’ unstable genome. Because cancerous cells divide and proliferate
rapidly, they accrue more genetic mutations which are ineffectively repaired or completely
bypassed by normal DNA damage repair mechanisms.4 Therefore, tumor cells are more
susceptible to the damaging effects of ionizing radiation compared to normal tissue cells.
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However, healthy tissue does not often go unaffected by the effects of radiation therapy.3

Acute and late effects are often observed as a consequence of irradiation. Acute effects
are those that normally occur within weeks of treatment and may persist for up to several months
upon the completion of therapy. These short-term effects are characterized by damage to tissues
that are rapidly proliferating, such as hair follicles or epidermal cells. As a result, conditions such
dermatitis, breast pain, and hyperpigmentation are often observed as side effects of
radiotherapy.3,5 Late effects usually arise between six months to several years after treatment.
These effects are often chronic, persisting for many years after undergoing treatment, and often
irreversible. These effects may include fibrosis and collagen reabsorption, causing hardening or
reduction of the irradiated breast tissue and nearby organs.3 Additionally, vascular damage can
significantly impact skin integrity and appearance.3,5 Because of the severe impact that
radiotherapy may have on healthy tissue, this limits the admissible treatment dosage for all
patients despite the fact that response to treatment varies between individuals.3 Although several
candidate genes have been identified that may contribute to differences in patient response, there
are currently no reliable biomarkers to predict responses to radiotherapy.6,7

MicroRNAs (miRNAs) have become a great area of interest in research, particularly in
the context of cancer. MiRNAs are short stretches of single-stranded, non-coding RNA that are
18-25 nucleotides in length and influence post-transcriptional gene expression by binding to and
destabilizing messenger RNAs (mRNAs).8,9 The effect that miRNAs have on cell activity lends
to their vast potential in applications such as risk factor assessment, diagnosis, progression
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monitoring, and treatment of breast cancer.8 MiRNA is produced in the nuclei of virtually all
eukaryotic cells. It is first transcribed from DNA into pri-miRNA which is cleaved to produce
pre-miRNA. This pre-miRNA is then transported to the cytoplasm and modified to produce
mature miRNA. The mature miRNA targets the 3’-UTR of its specific target mRNAs to alter the
transcription.9 MiRNA can affect mRNA transcription not only within its cell of origin but within
nearby cells as well as distant cells of different origins and cell types.10 MiRNA may be secreted
freely into the circulation bound to the protein Ago2 and may be found both intravascularly in
the plasma or serum and also extravascularly, such as in the saliva, breastmilk, urine, or amniotic
fluid.8,9,11 Over 2,000 mature miRNAs have been identified in humans. Many of these miRNAs
have been identified as being differentially expressed in various cancers. Several studies have
shown that tumor cells secrete miRNA in order to maintain the tumor microenvironment and
therefore enhance tumor growth and metastasis.10 Interest in research regarding miRNAs that are
transported and delivered specifically via extracellular vesicles (EVs) has increased dramatically
within the last decade.12,13

Exosomes are small, membrane-bound EVs 30-150 nm in size. They are released by
nearly all eukaryotic cells and are found in various biological fluids. Exosomes are similar to
other EVs such as microvesicles in that they are membrane-derived particles that are secreted by
cells into the extracellular space in order to mediate cell-to-cell communication.11,14 Compared to
microvesicles, they may also contain similar cargo; such as miRNA, mRNA, proteins, and lipids.
However, exosomes differ from other EVs in terms of their biogenesis, membrane composition,
size, trafficking mechanisms, and mechanism of content release.14 Exosome formation begins
with the endocytic pathway where clathrin-coated domains bud inward from the cell membrane
3

to produce the early endosome. As the endosome matures it gives rise to a multivesicular body
containing intraluminal vesicles whose formation is directed by the ESCRT (endosomal sorting
complex required for transport) pathway.14,15 ESCRT proteins are responsible for the
identification and wrapping of cargo within intraluminal vesicles as well as vesicle scission.16
There appears to be a few mechanisms by which specific miRNAs are selected for packaging
into exosomes. Passive loading of exosomes is based primarily on which miRNAs are most
highly concentrated in the cell. Active mechanisms may depend on particular sequence motifs at
the 3' end of the miRNA, which are recognized by specific proteins that assist their loading into
the exosomes.10 After exosome secretion via RAB and SNARE proteins, there appears to be
multiple mechanisms by which exosomes are recognized and subsequently taken up by their
target cells.16,17 This includes opsonization, chemokine release, and cell adhesion.15 Furthermore,
exosomes produced by immune cells express MHC class I and II, which may be recognized by T
cells.15,17 Uptake of exosomes into their appropriate target cells is thought to occur via receptorligand interactions, fusion of the exosome and cell membranes, and phagocytosis.15 Exosomal
miRNAs and other cargo may then be released into the cell where they alter cell activity.

The potential clinical applications of exosomal miRNAs continues to expand as
exosome biogenesis, cellular targeting, and miRNA functioning become more clearly
understood. Most notably, analysis of exosomal miRNA expression has gained notoriety as a
potential method for detecting tumor growth, metastasis, and examining the genetic profile of a
tumor.18 Identification of particular miRNAs that are associated with cancer development and
metastasis have highlighted the therapeutic possibility of targeting and therefore inhibiting the
action of specific tumorigenic miRNAs.9,18 Similarly, miRNAs that maintain homeostasis and
4

promote normal physiological signaling may provide another therapeutic strategy whereby these
miRNAs can be delivered to specific target cells.9,10

MiRNA expression analysis as an indicator of tumor radiosensitivity may yield
valuable information with the potential to improve radiation treatment, but has thus far been less
extensively explored compared to the aforementioned areas of miRNA research. Heterogeneity
across tumors lends to their varying sensitivity to radiotherapy, but predicting and characterizing
the exact nature of this heterogeneity remains a challenge.18 Studies focused on the topic of
miRNA expression in response to radiotherapy have identified particular miRNAs that may be
involved in tumor cell response to ionizing radiation. Griñán‐Lisón et al. identified eight
miRNAs linked to the variations in response of cancerous stem cells to radiotherapy.19
Additionally, Pajic et al. showed that miR-139-5p is associated with increased oxidative stress,
decreased DNA damage repair, and increased apoptosis in tumor cells.20 MiRNAs associated
with the toxicity response in normal tissue have received less investigative attention, however a
few studies have identified miRNAs that appear to promote tissue toxicity. In a 2019 study,
Esplugas et al. demonstrate that radiotherapy increases the expression of miRNA-155, -221, 146, and -222 in breast cancer patients, which have been linked to the development of
cardiovascular toxicity.21 In a separate study, miR-215 was also associated with cardiac toxicity
induced by radiotherapy in breast cancer patients.22 Additionally, research on glioblastoma
patients who received radiotherapy revealed that elevated expression of miR-10b and miR-21 is
associated with higher toxicity grade, while miR-34a appears to serve as a dosimeter for
radiation exposure.6 This study is similar to those previously mentioned, but investigates miRNA
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expression in patients with tumors of the central nervous system rather than breast cancer.
Furthermore, these studies do not investigate miRNA isolated from EVs. This highlights the
need for more studies that examine the effects of radiotherapy specifically on exosomal miRNA
expression in breast cancer patients.

The present study aims to identify exosomal miRNAs whose differential expression
prior to radiotherapy may serve as a predictor of the degree to which individual breast cancer
patients exhibit radiotoxicity in normal tissues. Such data is critical in order to identify reliable
biomarkers that can predict radiotoxicity. These biomarkers are necessary to minimize treatment
risk and maximize the benefit to each patient. This study utilizes qPCR as a high throughput
method to screen for hundreds of known miRNAs that have been purified from plasma samples
of patients whose toxicity responses range from minimal to severe. The miRNAs identified in
this study may not only serve as a biomarkers for post-radiation toxicity, but may help identify
the genetic processes that influence toxicity response. Therefore, the presented data may
contribute to the potential use of miRNA as a tool to improve personalized patient therapy.

6

MATERIALS AND METHODS

Patient Samples:
Blood samples drawn from 86 women diagnosed with breast cancer were used in the
present study. These blood samples were collected 1 day before the start of radiation treatment.
Patient samples were delegated to one of four groups depending on the patient’s reaction to
radiation. Samples delegated to Group 1 (n=9) were obtained from patients who exhibit minimal
toxicity in response to radiation. Group 2 (n=45) describes patients with moderate response to
radiation, while Group 3 (n=7) describes patients with severe acute reaction and Group 4 (n=25)
describes patients with severe long-term reaction. The blood samples were collected in tubes
coated with K2EDTA (Potassium Ethylene Diamine Tetra Acetic acid). This material acts as an
anticoagulant to prevent blood clotting. On the same day of collection, blood samples were
centrifuged at 3,000x g for 15 minutes at 4°C to obtain the plasma fraction, which was aliquoted
and saved in vapor phase of liquid nitrogen.

Extracellular Vesicles (EVs) Extraction:
EVs were isolated from patient plasma samples using the PureExo® Exosome Isolation
Kit for Serum and Plasma (101Bio, Palo Alto, CA, USA) according to the manufacturer’s
instructions. The concentration and size of EVs were measured using ZetaView® Nanoparticle
Tracking Analysis. All samples were diluted in 1xPBS to a final volume of two milliliters. Ideal
measurement concentrations were found by pre-testing the ideal particle per frame value (140–
200 particles/frame). The manufacturer’s default software settings for EVs were selected
accordingly. For each measurement, three cycles were performed by scanning 11 cell positions
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each and capturing 80 frames per position under the following settings: Focus: autofocus;
Camera sensitivity for all samples: 78; Shutter: 100; Scattering Intensity: detected automatically;
Cell temperature: 25°C. After capture, the videos were analyzed by the built-in ZetaView
Software 8.04.02 SP2 with specific analysis parameters: Maximum area: 1000; Minimum area:
5; Minimum brightness: 25; Hardware: embedded laser: 40 mW at 488 nm; Camera: CMOS. The
number of completed tracks in NTA measurements was always greater than the proposed
minimum of 1000 in order to minimize data skewing based on single large particles.

Transmission Electron Microscopy (TEM):
Isolated EVs were fixed and prepared for TEM. TEM analysis was carried out by the
Microscopy Core of VCU.

Western blotting (WB) and Antibodies:
Equal amounts of total protein from each sample were loaded and separated by SDSPAGE gel and transferred to nitrocellulose membranes. The membranes were exposed to the
following primary antibodies at specific dilutions: anti-CD9 (dilution 1:1000, Novus
Biologicals), anti-CD63 (dilution 1:1000, ThermoFisher), anti-TSG101 (dilution 1:500, Cell
Signaling), anti-Albumin (dilution 1:1000, Cell Signaling). Specific protein bands were detected
using the following infrared-emitting conjugated secondary antibody: anti-rabbit DyLight™ 800
4X PEG Conjugate (dilution 1:10,000, Cell Signaling). WB images were generated and analyzed
using the ChemiDoc Infrared Imaging System (Bio-Rad).
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RNA Purification:
MicroRNA was purified from isolated exosome samples using the MiRNeasy Micro Kit
(Qiagen, Hilden, Germany) according to the manufacturer’s protocol with a few modifications to
maximize the recovery of miRNA from EVs. Synthetic Spike-in UniSp-2-4-5 miRNA controls
(Qiagen, Hilden, Germany) were added to 200 μL of EV sample and homogenized with 750 μL
of TRIzol™ LS reagent (Invitrogen, Carlsbad, CA, USA), followed by 200 μL of chloroform.
Each sample was vortexed for sixty seconds and incubated at room temperature for five minutes.
Phase separation was performed by centrifuging the samples at 12,000×g for fifteen minutes at
4°C. Three hundred microliters of the upper aqueous phase was transferred to a new tube.
Glycogen (5 mg/mL; Invitrogen, San Diego, CA, USA) for miRNA precipitation was added to
this aqueous phase before being mixed with 1000 μL of cold 100% molecular grade ethanol. The
tube was vortexed for thirty seconds and incubated at − 80 °C for one hour to allow miRNA
precipitation. After precipitation, samples were transferred to a Qiagen RNeasy® Mini spin
column in a collection tube followed by centrifugation at 15,000 × g for thirty seconds at room
temperature. The Qiagen RNeasy® Mini spin column was rinsed with 700 μL Qiagen RWT
buffer and centrifuged at 15,000 × g for thirty seconds at room temperature. This was followed
by another rinse with 500 μL Qiagen RPE buffer and centrifugation at 15,000 × g for thirty
seconds at room temperature. Eighty percent ethanol was then added to the column and
centrifuged at 15,000 x g for one minute at room temperature. The column was then transferred
to a new microcentrifuge tube and and centrifuged according to the manufacturer’s instructions
in order to dry the membrane. The column was again transferred to a new microcentrifuge tube
with the lid left uncapped for one minute to allow the column to dry further. Eighteen microliters
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of RNase-free pre-warmed (+65°C) water was then added to the dry column. After one minute of
incubation, total EV-miRNA was eluted by centrifugation at 15,000 × g for one minute. The
samples with total EV-miRNA were stored in a freezer at −80°C. The concentration and purity
of the EV-miRNA samples were measured using NanoDrop ND-1000 spectrophotometer
(Thermo Scientific, Wilmington DE).

RT and qPCR reactions:
EV-miRNA samples were diluted with RNase-free water to a concentration of 5 ng/μL as
instructed by the miRCURY® LNA® RT Kit protocol (Qiagen, Hilden, Germany). 5x miRCURY
RT Reaction Buffer, 10x miRCURY RT Enzyme Mix, and UniSp6 synthetic spike-in control
were added to each template RNA in accordance with the manufacturer’s instructions. Ten
microliters of reaction mixture were loaded into the Biometra TRIO PCR Thermal Cycler.
Samples were incubated at 42°C for 90 minutes, then incubated at 95°C for five minutes and
then immediately cooled at 4°C.
For qPCR analysis of differential miRNA expression between the four toxicity groups,
the miRCURY LNATM miRNA Serum/Plasma PCR Panel (Qiagen, Hilden, Germany) was used.
The panel contains 2x179 LNA miRNA primer sets commonly found in human serum and
plasma. Each panel also contains sets of negative controls (H2O), and five sets of the following
RNA Spike-in controls: UniSp-2-4-5 (concentration ratio 10000:100:1) – for control of RNA
purification; UniSp6 – for control of cDNA synthesis; UniSp3 – for inter-plate calibration. The
amplification was performed in a QuantStudio 5 Real-Time PCR System (Thermo Fisher
Scientific, USA) in 384 well plates. The plates are produced in ready-to-use format: primer sets
are dispensed and lyophilized in the wells in amounts sufficient for one 10 µL reaction per
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well. The Serum/Plasma Focus miRNA PCR Panels also contain seven potential reference genes:
a) miR-103-3p, miR-191-5p and miR-423-5p; b) miR-93-5p and miR-425-5p: these potential
reference genes are chosen because they are usually stably expressed in serum/plasma; c) miR451a and miR-23a-3p: these can be used as a control for hemolysis. If ∆Ct(miR-23a-3p – miR451a) is >7, it may be an indication of excessive hemolysis.
All cDNA samples of each group were pooled together. The miRCURY LNATM miRNA
Serum/Plasma PCR Panel was run with equal amounts of the pooled cDNA samples for each
group according to the manufacturer’s instructions. The real-time PCR data was normalized by
ROX (carboxy-X-rhodamine) passive reference.

Data Analysis:
The amplification curves were analyzed using the QuantStudio™ Design & Analysis
Software v1.4.2, both for determination of Ct values and for melting curve analysis. All assays
were inspected for distinct melting curves and the Tm was checked to be within known
specifications for each particular assay.
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RESULTS:

EVs were precipitated from 0.5 mL plasma samples and reconstituted in 0.2 mL of
1xPBS buffer. The Nanoparticle Tracking Analysis demonstrated that EV concentration in the
native plasma before exosome precipitation was equal to 1.9x1011 particles/mL, and the
concentration of EVs after precipitation and resubmission in 0.2 mL of 1xPBS buffer was equal
to 3.5x1011 particles/mL (Figure 1). Analysis of the plasma sample after EV extraction showed a
significant decrease in the concentration of EVs; the concentration of this EV-depleted plasma
was 3.7x105 particles/mL (Figure 1). This means that >99% of the EVs were effectively
precipitated from the plasma samples. If 100% of EVs had been collected from 0.5 mL of plasma
into 0.2 mL of 1xPBS then the concentration factor would be 2.5, and the EV concentration in
1xPBS buffer would be equal to 4.75x1011 particles/mL. However, the final concentration of the
extracted EVs was 3.5x1011 particles/mL, indicating that ~74% of precipitated EVs were released
from the precipitation pellet, and ~26% remained trapped. These results are comparable to the
published literature results for EV isolation from plasma using the PureExo® Exosome Isolation
Kit.25 Based on these results and those from previously published literature, the EVs isolated are
thought to primarily consist of exosomes.4,11
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Figure 1. Nanoparticle tracking analysis (ZetaView®) exosome concentration and size
representation in the plasma sample: (A) whole plasma before exosome isolation; (B) fraction
of the extracted exosomes (extracted-Exo); (C) exosome-depleted plasma (dep-Exo).
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Isolated EVs were additionally characterized by transmission electron microscopy (TEM)
and Western blot (WB) analysis of the specific EV markers. The TEM image of the isolated EVs
demonstrated multiple spherical particles with the size range close to 100 nm (Figure 2A). WB
analysis was performed for the equal amounts of total protein form the native plasma, isolated
EVs, and exosome-depleted plasma. There was significant accumulation of the EV markers
CD9, CD63, and TSG101 in the isolated EV sample compared with the native plasma and EVdepleted plasma samples (Figure 2B). Isolated EVs also showed significantly lower levels of the
plasma protein albumin in comparison with whole plasma and EV-depleted plasma, which
indicates a low contamination of isolated EVs with plasma proteins (Figure 2B). MiRNA
purification from EV samples produced an average concentration of 18.51±5.29 ng/μL. Each
miRNA sample was eluted in 18μL, thus an average of 333.22±90.13 ng of miRNA was purified
from each EV sample. The 260/280nm absorbance ratio for each miRNA sample was between
1.7-2.0. Previous studies which have also used the MiRNeasy Micro Kit system have shown
similar effectiveness for RNA purification.27,28
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Figure 2. Analysis of the extracted exosomes. (A) Transmission electron microscopy image of
the extracted exosomes; bar = 100nm. (B) The expression of CD9, CD63 and TSG101, as well as
albumin in the isolated particles was determined by western blotting. Lanes from left to right are
whole plasma (before exosome extraction), fraction of the extracted exosomes (Exo), and
fraction of the exosome-depleted plasma (de-Exo) respectively.
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After cDNA synthesis, equal amounts of each sample from the same toxicity group were
pooled together for each panel. The pooled cDNA samples for each group were analyzed for
expression of 179 miRNAs commonly found in serum/plasma samples with SYBR® Green
Master Mix. Melting curve analysis demonstrated single distinct peaks in the plots for the
negative derivative of fluorescence vs. temperature for each probe, including Spike-in controls
(Figures 3, 4A). Results from RT-PCR revealed a total of 24 miRNAs that were differentially
expressed between the previously described toxicity groups (Table 1). Additionally, five
miRNAs were identified as potential normalization controls, as they demonstrated very close
expression levels for all groups. Some of these miRNAs (e.g. miRNA-16-5p) have been
previously reported as reliable internal controls for extravesicular miRNA analysis29. Spike-in
controls 2-4-5 showed uniform expression levels across all four toxicity groups, which exhibit
ratios close to the ratios in which they were added to the EV samples (Figures 4B, 4C). The ideal
ratio for the Unisp-2-4-5 is 10000:100:1. The ratio obtained for the four pooled samples was
10000:68.46±2.32:0.5±0.03 (Figure 4).

Figure 3. Melting curves for 24 miRNAs demonstrated a high potential in the prediction of
16

post-RT toxicity of breast cancer patients and five miRNAs as potential normalization
controls.

Table 1. Potential miRNA candidates for prediction of post-RT normal tissue toxicity and
17

potential normalization controls. MiRNA-165p was used as a normalization control to
calculate ΔCt values.

Figure 4. UniSp2-4-5 expression analysis: (A) Melting curves for UniSp2-4-5 spike-in control
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RNAs. (B) Amplification plots of UniSp2-4-5 for all four groups. (C) Relative expression of
UniSp2-4-5 for Groups 1-4.
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B.

20

21

C.

Although the relative expression ratios for Unisp2-4-5 indicates that less concentrated
miRNAs were purified with somewhat less efficiency than more highly concentrated miRNAs,
the very small deviation between the pooled samples demonstrates a very high accuracy and
reproducibility of this miRNA purification method. Expression of EV-miRNAs for all toxicity
groups were normalized by Spike-in controls, and ∆Ct values were calculated by using miRNA16-5p as an internal control. MiRNAs that demonstrated significant expression differences
between the pooled samples were divided into four different groups (Table 1). As potential
predictors for Group 1, nine miRNAs (miR-10b-5p, miR-133a-3p, miR144-5p, miR-152-3p,
miR-18a-5p, miR-197-3p, miR-200c-3p, miR-222-3p, miR32-5p) showed negligible expression,
whereas Groups 2, 3, and 4 showed relatively high and similar expression for each of these
miRNAs. The same tendency in expression was demonstrated for miR-29-5p. The ∆Ct value for
this miRNA was 13.31 for Group 1, 5.53 for Group 2, 4.36 for Group 3, and 3.55 for Group 4.
22

Eight miRNAs were identified as prediction candidates for Group 3. Six miRNAs (miR151a-3p, miR-192-5p, miR-215-5p, miR-34a-5p, miR-423-3p, miR-425-3p) showed no
expression, whereas Groups 1, 2, and 4 showed relatively high expression for all these miRNAs.
Expression of miR-130a-3p was significantly lower in Group 3 (∆Ct value = 17.41) compared to
Group 1 (∆Ct value = 3.68), Group 2 (∆Ct value = 5.45), and Group 4 (∆Ct value = 4.75). MiR200a-3p demonstrated a relatively high level of expression (∆Ct value = 6.55) whereas
expression of the same miRNA in Groups 1, 2 , and 4 was undetermined.
Additionally, six EV miRNAs were identified as potential biomarkers for both Groups 3
and 4. MiR-146b-5p, miR-154-5p, miRNA-18b-5p, and miR-335-3p demonstrated significantly
lower or negligible expression levels in Groups 3 and 4 compared to Groups 1 and 2. Mir-376c3p showed no expression in Groups 1 and 2 with moderate expression in Group 3 (∆Ct value =
18.65) and a high expression level in Group 4 (∆Ct value = 5.78). Interestingly, only mir-328-3p
demonstrated a significant expression difference for all four groups with a steady increase in ∆Ct
from Group 1 to Group 4: 4.94, 6.63, 13.44, and 21.47, respectively.
Finally, five miRNAs were identified as potential normalization controls: miR-16-5p,
miR-451a, let-7i-5p, miR-21-5p, and miR-1260a.
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DISCUSSION

The ZetaView® Nanoparticle Tracking Analysis (NTA) results show isolated particles
with an average diameter characteristic of extracellular vesicles. Based on adherence to the
PureExo® kit protocol and the size distribution of the particles, it is suspected that the isolated
particles are primarily exosomes, but this cannot be determined from NTA results alone. Taken
together with our western blot results, the identity of the isolated EVs can more clearly be
elucidated. The concentration of classical exosome markers CD9, CD63, and TSG101 in the
isolated EV fraction appeared much higher compared to the whole plasma and exosome-depleted
fractions. It should, however, be noted that these proteins are present to some degree in other
subpopulations of EVs and can also be found freely circulating in plasma.17 Furthermore,
although our observed particle size and concentration of exosomes are similar to some existing
publications, varying results have also been published. While some research has claimed
exosome concentration to range from 0.88x108 to 13.38 x 108 exosomes/mL of plasma, others
have reported that between 8.35x109 and 10.9x109 exosomes/mL are found in breast cancer
patients, with particle size averaging 95nM for patients with localized tumors and 125nM for
those with metastasis.26,31 One likely explanation for the differences in reported concentrations is
the use of different isolation methods.32,33 In a study that utilized the PureExo® system with
serum from healthy donors, only 7.1 x 107 particles per 0.5mL were obtained.25 This highlights
other factors that may cause differences in the concentrations and morphology of isolated EVs,
such as extraction from serum versus plasma, differences in the pathological state of the patients
from which the samples are obtained, differences in the particle analysis methods utilized, and
24

variations in adherence to isolation protocol.34,35 In the present study, the PureExo® isolation kit
was chosen as a polymer precipitation method for isolating exosomes with high enough purity
suitable for miRNA purification and PCR analysis.25,36
According to the qPCR results, miRNA purification of EV samples was performed
efficiently, with qPCR curves for UniSp-2-4-5 showing an expression ratio close to the expected
10000:100:1 ratio with little variation between samples. Furthermore, the 260/280 absorbance
spectra for each purified sample was within the range accepted as pure for RNA isolation.37 The
MiRNeasy Micro Kit protocol is a phenol/chloroform-based extraction method that is followed
by purification of small RNAs by filtration of remaining contaminants through a silica
membrane spin column.27 MiRNAs are then eluted from the column using RNase-free water.
This system has been shown in previous publications to isolate miRNA of higher quality
compared to other kits, which is important for downstream PCR applications.27 Furthermore, the
miRCURY LNATM miRNA Serum/Plasma PCR Panel was chosen for miRNA expression
analysis as it screens for 179 miRNAs of which are known to be expressed in plasma and are of
particular interest based on previously published research.38
The 24 miRNAs that have been identified in this study as being differentially expressed
between the four radiotoxicity groups may serve as candidates for predictors of radiotoxicity in
breast cancer patients, while miR-16-5p, miR-451a, let-7i-5p, miR-21-5p, or miR-1260a may
serve as normalization controls. Of these 29 total miRNAs, several have been previously studied
in the context of breast cancer. A few have been explored in relation to chemotherapy resistance
and even fewer have been mentioned regarding irradiation response. For example, miR-18-a has
been determined to cause radiosensitizing effects in lung cancer stem-like cells, however
expression was analyzed from whole plasma rather than EVs.39 Perhaps this miRNA is also
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responsible for sensitizing healthy tissue to irradiation in breast cancer, as our data showed that
this miRNA was not expressed in patients with minimal reaction to radiation compared to those
who showed normal to severe effects. The presented data also determined that miR-222-3p is
downregulated in Group 1. This miRNA has been previously described as a “double-edged
sword” because low expression of this miRNA in serum was associated with higher response to
Trastuzumab and therefore better survival rates in HER-2 positive patients, but simultaneously
promotes cardiotoxicity.40 Perhaps this miRNA plays different roles in response to chemotherapy
compared to radiation, as it has also been noted by previous publications that the exact role of
miR-222-3p requires further clarification.
The only miRNA expressed at detectible levels in patients with minimal toxicity was
miR-29a-3p, although it was still expressed at lower levels compared to Groups 2-4. In the
context of breast cancer, this miRNA is thought to be associated with poor patient prognosis by
acting as an upstream regulator of SETDB1 in the BRCA gene.41 Its response to irradiation has
also been examined in oral squamous cell carcinoma cell lines, whereby it appears to enhance
tumor cell sensitivity to radiotherapy.42 These studies do not examine miRNA expression in
vivo, but it is possible that the increased expression of this miRNA in Groups 2-4 reflects its
function in enhancing healthy tissue sensitivity to radiotherapy.
Of the miRNAs that differentiate Group 3 from the other three groups, miR-34a-5p has
been recognized by previous publications regarding its response to irradiation in breast cancer
patients. It was found that the concentration of this miRNA from isolated leukocytes increases in
response to radiation and appears to play a role in tumor growth suppression by inhibiting
double-stranded break repair.43 MiR-34a-5p was least expressed in Group 2 patients, followed by
Groups 1 and 4, and was not expressed in Group 3. Further research is necessary in order to
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better understand the role of miR-34a-5p that is causing this differential expression.
Six miRNAs showed similar expression in Groups 3 and 4 compared to patients who
experience minimal or moderate toxicity. For example, miR-328-3p has been associated with the
suppression of breast cancer progression as well as the sensitization of non-small cell lung cancer
and osteosarcoma to radiotherapy.44,45 Perhaps the mechanisms by which this miRNA sensitizes
tumor tissue to irradiation contrast to those that sensitize healthy tissue to radiotoxicity since this
miRNA was expressed significantly less in Groups 3 and 4 compared to Groups 1 and 2. These
studies, however, analyze miRNA expression from tumor tissue and nearby non-tumor tissues
rather than circulating EVs. This averts the focus away from miRNAs that are transported in the
blood to mediate communication between cells, and instead limits the scope of study to miRNAs
which may only be expressed within their cell of origin as a consequence of exposure to
radiation. This, therefore, does not contribute to data that is needed in order to establish a
reference for liquid biopsy.
The exact causes for higher or lower expression of particular miRNAs in certain patients
compared to others prior to irradiation are largely unknown, but it does appear that patients who
exhibit minimal tissue response to irradiation naturally produce lower levels of EV miRNA that
influence irradiation responses such as acute inflammation, tissue fibrosis and vascular damage.
The exact mechanisms by which these miRNAs influence tissue response also requires further
research. It is has been demonstrated that miR-222, for example, influences inflammationmediated neovessel formation.21 Its upregulation has been associated with antiproliferation and
apoptosis in endothelial cells, while promoting the opposite effects in smooth muscle cells.21
Esplugas et al. determined that miR-222, as well as miR-146a, -155 and -221 were increased in
association with cardiotoxicity in breast cancer patients, supporting previous findings that these
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miRNAs promote inflammation, oxidative stress, and atherosclerosis.21 In our presented data,
EV miR-222-3p was not detected in Group 1, but was expressed at comparable levels for Groups
2-4. Together with previously published literature, this suggests that the miR-222 cluster of
miRNAs targets mRNAs which influence protective effects in normal tissue. Identifying the
respective mRNA targets of particular miRNAs would provide insight as to their mechanism of
action and perhaps why expression levels vary between individuals before or after radiotherapy.
Several previous studies have described particular miRNAs as endogenous control
candidates for data normalization. In particular, let-7a-5p, miR-21-5p, and miR-16-5p have
shown stable expression in healthy, benign, and malignant tissue.29 Our data determined miR-165p to be the most stably expressed, which has been deemed the best endogenous control
particularly for the study of metastatic breast cancer.29 These miRNAs are deemed
“housekeepers,” meaning that they are responsible for basic cellular functioning and therefore
highly conserved and equally expressed in most cells.46 This provides a standard by which to
adjust expression data for biological and analytic variations.46

The importance of the data obtained from this study is the identification of new potential
biomarkers for radiotoxicity response. This may ultimately help predict patient response to
radiotherapy and therefore help optimize patient treatment plans accordingly. As pointed out by
studies that address tumor response to radiation, it may be futile to administer radiotherapy to
patients whose tumors express miRNAs associated with tumor radioresistance.3 Our findings
take this notion a step further by considering that perhaps patients with particular miRNAs
associated with severe levels of toxicity in addition to those associated with tumor resistance
might avoid or at least limit radiotherapy as a primary form of treatment.
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There is also a potential future in the use of miRNA as a therapeutic agent for sensitizing
tumor tissues to radiation while protecting surrounding tissues. Administration of miRNAs
associated with minimal adverse reaction or perhaps inhibiting those that promote toxicity are
possible avenues for therapy.47 Electroporation and transfection are two mechanisms by which
specific miRNAs or other therapeutic drugs may be loaded into exosomes.48 In addition to
exosomes, bioengineered non-viral nanoparticles (NPs) offer a biocompatible and easily
produced method for nucleic acid delivery. These include inorganic NPs such as gold
nanoparticles as well as organic NPs such as micelles and lipid NPs.49 However, there are several
challenges that must be overcome before the widespread implementation of vesicle-delivered,
miRNA-based therapy. Namely, the exact mechanism of exosome recognition and uptake by its
intended cell targets is not well known.12 Furthermore, miRNAs have multiple mRNA targets,
and their roles in various tissues are not always well known. Therefore, it is possible that
delivering or inhibiting specific miRNAs for therapeutic benefit could also have unintended
negative side effects.50
In order for any application of the presented data to be implemented, further studies must
be conducted. Performing PCR for each individual patient sample is needed to verify the
presented results due to the possibility of outlier samples skewing the data. After ruling out
particular miRNAs based on this information, miRNAs that remain statistically significant
require further study to determine their role and significance in radiotoxicity response.
Furthermore, the data must be normalized for variables such as patient age, race, cancer stage,
adjuvant treatment, and other health conditions. Subsequent experiments following the same
protocol but with plasma samples obtained during and after treatment should also be performed.
This may provide valuable information regarding the physiological processes that occur in
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response to radiation treatment. This would likely yield interesting results especially considering
that Stepanović et al. determined that the most significant alteration in miRNA expression in
response to radiotherapy occurs halfway through radiation treatment in glioblastoma patients.7
Their study found that baseline levels of non-EV miR-21 in plasma were higher in patients who
exhibited toxicity response in normal tissue, with expression levels significantly increased
halfway through radiation treatment. Patients with lower circulating levels of miR-21 before
radiotherapy had better outcomes in their normal tissue response to radiotherapy, whereas
patients with higher circulating levels prior to treatment appeared to experience toxic effects as a
result of the increase in miR-21 that occurs in response to treatment. Furthermore, higher
baseline levels of miR-10b were observed in patients exhibiting toxicity compared to patients
without toxicity. MiR-10b levels for patients with toxicity slightly decreased halfway through
irradiation treatment. Interestingly, levels of expression in patients without toxicity response
were decreased at this time point, but were increased after the last treatment dosage to levels
very close to that of baseline for toxicity patients.7 Considering that the ∆Ct values for miR-10b5p were much higher for Groups 2-4 compared to Group 1, it would be interesting to analyze BC
patient samples obtained after radiation to see if the same trend is observed.
As of present, data that is closely comparable to that which is presented in this paper has
not been published. Studies which have investigated miRNA biomarkers indicative of
radiotoxicity in breast cancer patients use different methods for purification and analysis or do
not evaluate miRNAs isolated from EVs. Furthermore, existing studies evaluate patients who
receive different radiotherapy dosages and schedules, and do not evaluate toxicity on the same
basis. For example, Esplugas et al. focus strictly on cardiotoxicity associated with circulating
miRNAs that are not contained within EVs.21 Other publications may evaluate patients who do
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or do not exhibit radiotoxicity in general, but they do not differentiate between patients who
experience acute versus chronic effects.7 In turn, this has likely decreased the number of
comparable publications available. Reproducibility is a frequent challenge in exosomal miRNA
research given the plethora of isolation methods and materials available.51 Additionally, there are
no universally accepted miRNAs for use as normalization controls.51 These challenges as well as
many others must be met before the possibility of clinical applications.
The data presented in this study provides the initial findings necessary for further
examination in this area of exosomal miRNA research. Twenty-four miRNAs that are
differentially expressed between groups of breast cancer patients based on the response of their
normal tissue to radiotherapy have been identified, as well as five miRNAs that are stably
expressed and may serve as normalization controls. It would be particularly interesting to further
examine some of the miRNAs discussed above which have also been shown in previous
publications to play a role in radiotherapy response. Future studies using the same protocol
implemented in this research would contribute significantly to the lack of comparable studies and
may therefore expand upon and affirm the results of the presented data.
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